Literature DB >> 22973419

Management of hepatitis B reactivation in patients receiving cancer chemotherapy.

Yi-Wen Huang1, Raymond T Chung.   

Abstract

Hepatitis B virus (HBV) reactivation is well documented in previously resolved or inactive HBV carriers who receive cancer chemotherapy. The consequences of HBV reactivation range from self-limited conditions to fulminant hepatic failure and death. HBV reactivation also leads to premature termination of chemotherapy or delay in treatment schedules. This review summarizes current knowledge of management of HBV reactivation in patients receiving cancer chemotherapy. HBV surface antigen (HBsAg) testing should be performed in patients who require cancer chemotherapy. Four meta-analyses support lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients. Randomized controlled trials to compare different HBV antiviral agents are needed to define optimal regimens for the prevention and treatment of HBV reactivation in patients receiving cancer chemotherapy.

Entities:  

Keywords:  HBV reactivation; cancer; chemotherapy; hepatitis B virus; lamivudine; prophylaxis

Year:  2012        PMID： 22973419      PMCID： PMC3437537          DOI： 10.1177/1756283X12450245

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


  77 in total

1.  Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan.

Authors:  K Kumagai; T Takagi; S Nakamura; U Sawada; Y Kura; F Kodama; S Shimano; I Kudoh; H Nakamura; K Sawada; T Ohnoshi
Journal:  Ann Oncol       Date:  1997       Impact factor: 32.976

2.  Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.

Authors:  Dongmei Ji; Junning Cao; Xiaonan Hong; Junmin Li; Jianmin Wang; Fangyuan Chen; Chun Wang; Shanhua Zou
Journal:  Eur J Haematol       Date:  2010-05-20       Impact factor: 2.997

3.  Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

Authors:  Ming-Shen Dai; Tsu-Yi Chao; Woei-Yau Kao; Rong-Yaun Shyu; Tan-Mei Liu
Journal:  Ann Hematol       Date:  2004-08-25       Impact factor: 3.673

4.  Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.

Authors:  R Idilman; M Arat; E Soydan; M Törüner; I Soykan; H Akbulut; O Arslan; M Ozcan; A R Türkyilmaz; M Bozdayi; S Karayalçin; D H Van Thiel; A Ozden; M Beksaç; H Akan
Journal:  J Viral Hepat       Date:  2004-03       Impact factor: 3.728

5.  Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model.

Authors:  Sammy Saab; Mamie H Dong; Tom A Joseph; Myron J Tong
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

6.  A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.

Authors:  Chiun Hsu; Chao A Hsiung; Ih-Jen Su; Wei-Shou Hwang; Ming-Chung Wang; Sheng-Fung Lin; Tseng-Hsi Lin; Hui-Hua Hsiao; Ji-Hsiung Young; Ming-Chih Chang; Yu-Min Liao; Chi-Cheng Li; Hung-Bo Wu; Hwei-Fang Tien; Tsu-Yi Chao; Tsang-Wu Liu; Ann-Lii Cheng; Pei-Jer Chen
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

7.  Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients.

Authors:  L L Lim; C T Wai; Y M Lee; H L Kong; R Lim; E Koay; S G Lim
Journal:  Aliment Pharmacol Ther       Date:  2002-11       Impact factor: 8.171

8.  American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.

Authors:  Andrew S Artz; Mark R Somerfield; Jordan J Feld; Andrew F Giusti; Barnett S Kramer; Anita L Sabichi; Robin T Zon; Sandra L Wong
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

9.  Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience.

Authors:  Min Kyoung Kim; Jin Hee Ahn; Sung-Bae Kim; Young-Suk Im; Soon Im Lee; Sei-Hyun Ahn; Byung Ho Son; Gyungyub Gong; Hak-Hee Kim; Woo Kun Kim
Journal:  Korean J Intern Med       Date:  2007-12       Impact factor: 2.884

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640
View more
  7 in total

Review 1.  Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

Authors:  Michael Sandherr; Marcus Hentrich; Marie von Lilienfeld-Toal; Gero Massenkeil; Silke Neumann; Olaf Penack; Lena Biehl; Oliver A Cornely
Journal:  Ann Hematol       Date:  2015-07-21       Impact factor: 3.673

2.  Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.

Authors:  Wei Tang; Lun Chen; Ruohui Zheng; Lingxiao Pan; Jin Gao; Xigang Ye; Xiaoshen Zhang; Wenbo Zheng
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

3.  Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.

Authors:  Ioanna Aggeletopoulou; Christos Konstantakis; Spilios Manolakopoulos; Christos Triantos
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742

4.  Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan.

Authors:  Ling-Yi Wang; Sung-Chao Chu; Yin Lo; Yen-Yun Yang; K Arnold Chan
Journal:  JAMA Netw Open       Date:  2021-04-01

5.  Case Report: In Situ Vaccination by Autologous CD16+ Dendritic Cells and Anti-PD-L 1 Antibody Synergized With Radiotherapy To Boost T Cells-Mediated Antitumor Efficacy In A Psoriatic Patient With Cutaneous Squamous Cell Carcinoma.

Authors:  Jun-Wei Huang; Chun-Lin Kuo; Li-Tzu Wang; Kevin Sheng-Kai Ma; Wen-Yen Huang; Feng-Cheng Liu; Kuender D Yang; Bing-Heng Yang
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

6.  Primary seronegative but molecularly evident hepadnaviral infection engages liver and induces hepatocarcinoma in the woodchuck model of hepatitis B.

Authors:  Patricia M Mulrooney-Cousins; Ranjit Chauhan; Norma D Churchill; Tomasz I Michalak
Journal:  PLoS Pathog       Date:  2014-08-28       Impact factor: 6.823

7.  RFX1 participates in doxorubicin-induced hepatitis B virus reactivation.

Authors:  Jie Wang; Junqiao Jia; Ran Chen; Shanlong Ding; Qiang Xu; Ting Zhang; Xiangmei Chen; Shuang Liu; Fengmin Lu
Journal:  Cancer Med       Date:  2018-03-30       Impact factor: 4.452
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.